Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Heterogeneity of treatment regimens and related health resource use in managing patients with waiha: A US multi-database retrospective observational Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAlexander LitvintchoukLJLouis JacksonZCZia Choudhry

Discussion

Loading...

Member takes

Overview

Observational study reveals high healthcare resource utilization and varied rituximab use in patients with warm autoimmune hemolytic anemia.

Key Points

  • This research aims to describe treatment patterns for patients newly diagnosed with warm autoimmune hemolytic anemia and evaluate healthcare resource utilization.
  • Retrospective observational study using multiple US databases to identify newly diagnosed wAIHA patients.
  • Evaluated treatment regimens including oral corticosteroids, immunosuppressants, and rituximab.
  • Analyzed healthcare resource utilization including hospitalization, blood transfusions, and outpatient visits.
  • Among 2,028 wAIHA patients, 64% received OCS monotherapy, while 28% received rituximab or immunosuppressants.
  • 1 in 4 treated patients required blood transfusions within 12 months; 35% required hospitalization.
  • The median time from diagnosis to first rituximab administration was 59 days; treatment patterns showed high deviation from standard practices.

Cite This Study

Litvintchouk et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e09bhttps://doi.org/10.1182/blood-2025-708
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment patterns and outcomes among warm autoimmune hemolytic anemia patients receiving rituximab in the United States: A retrospective database study2025
  2. 2[Future directions in the management of warm autoimmune hemolytic anemia].2025
  3. 3Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis2025
  4. 4Real-world evidence from China: Clinical characteristics, treatment landscape and long-term outcomes in 566 autoimmune hemolytic anemia patients2025
  5. 5Efficacy of daratumumab in treatment of relapsed and/or refractory warm autoimmune hemolytic anemia in children2025